메뉴 건너뛰기




Volumn 67, Issue 2, 2015, Pages 582-583

Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MESALAZINE; METHOTREXATE; NEUTRALIZING ANTIBODY; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; YELLOW FEVER VACCINE; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

EID: 84922791598     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38960     Document Type: Note
Times cited : (31)

References (3)
  • 3
    • 84860577315 scopus 로고    scopus 로고
    • Review of the risks and benefits of yellow fever vaccination including some new analyses
    • Monath TP,. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012; 11: 427-48.
    • (2012) Expert Rev Vaccines , vol.11 , pp. 427-448
    • Monath, T.P.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.